Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15495692 | 0.85 | TLR8 (0.36) | CYP11B1CYP11B2TLR8DAOSMN1; SMN2 | |
| SCHEMBL2202031 | 0.78 | CYP11B1 (0.49) | CYP11B1CYP11B2SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL521971 | 0.76 | IDO1 (0.40) | TLR8 | |
| SCHEMBL3749196 | 0.75 | CYP11B1 (0.43) | CYP11B1CYP11B2DAOCYP3A4CYP2C9 | |
| SCHEMBL29718750 | 0.73 | TLR8 (0.36) | CYP11B1CYP11B2TLR8DAOSMN1; SMN2 | |
| SCHEMBL19879597 | 0.73 | MAPK1 (0.47) | CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL19055348 | 0.73 | CYP3A4 (0.48) | CYP11B1CYP11B2TLR8CYP3A4 | |
| SCHEMBL28782435 | 0.73 | TLR8 (0.36) | CYP11B1CYP11B2TLR8DAOSMN1; SMN2 | |
| SCHEMBL1865390 | 0.72 | HCAR2 (0.38) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL20554634 | 0.72 | TLR8 (0.40) | TLR8DAOSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | CYP11B1 823/4885CYP11B2 1164/4885TLR8 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.